Heart Failure Drug Dosing: Simplified & Safe?
- A new study indicates that simplifying the dosing of heart failure medication, specifically vericiguat, might potentially be a safe and effective approach. The research, presented at the European...
- Heart failure with reduced ejection fraction affects an estimated 32 million people worldwide.
- The study,led by Stephen Greene,associate professor at Duke University School of Medicine,explored the impact of a simplified dosing regimen on heart failure medication.
New research revolutionizes heart failure treatment. The study unveils that starting the heart failure drug vericiguat at 5 mg, rather of the conventional 2.5 mg, is safe, potentially offering a streamlined, simpler approach. this simplification, reducing dosing steps, aims to improve patient outcomes and lower hospitalization risks for the millions battling heart failure with reduced ejection fraction. Conducted across seven countries, the study provides compelling evidence supporting the safety and tolerability of the enhanced dosing regimen.This update from News Directory 3 could reshape clinical guidelines and improve strategies for heart failure medication. Discover what’s next …
Simplified Heart Failure Medication Dosing shows Promise
A new study indicates that simplifying the dosing of heart failure medication, specifically vericiguat, might potentially be a safe and effective approach. The research, presented at the European Society of Cardiology conference on May 17, 2025, and published in the European Journal of Heart Failure, suggests that patients with heart failure and reduced ejection fraction could safely begin vericiguat at a 5 mg dose instead of the standard 2.5 mg.
Heart failure with reduced ejection fraction affects an estimated 32 million people worldwide. This condition impairs the heart’s ability to pump blood effectively, leading to increased risks of adverse events and hospitalizations. While medications exist, many patients do not reach target doses, exacerbating these risks.
The study,led by Stephen Greene,associate professor at Duke University School of Medicine,explored the impact of a simplified dosing regimen on heart failure medication. Greene said reducing the titration steps could help overcome clinical inertia in achieving target doses for heart failure medication. The research indicates that streamlining the process from three steps to two could improve patient outcomes.
“In real-world practice, most patients never achieve the target doses of recommended heart failure medications,” Greene said.
The study involved 106 patients across seven countries who initiated vericiguat at 5 mg over two weeks. Researchers compared the safety and tolerability of this higher dose with the standard 2.5 mg starting dose. Results showed comparable safety profiles,with over 90% of patients tolerating the 5 mg starting dose.
“I think simplicity is the key when we talk about implementation of heart failure medications in clinical practice,” Greene said.
Greene added that simplifying the initiation and titration of heart failure medications may help overcome logistical challenges in busy clinics and improve patient care. The study was funded by Bayer AG and Merck Sharp & Dohme LLC, manufacturers of vericiguat.
What’s next
Further research is needed to assess the long-term effects of simplified heart failure medication dosing on patient outcomes and hospitalization rates. The findings could lead to revised clinical guidelines and improved treatment strategies for millions affected by heart failure.